Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C – a randomized trial

Nutrition Journal

Gabriela Radulian¹  Dan Mircea Cheţa¹  Victor Stoica³  Simona Ateia⁴  Irina Sima⁵  Raluca Nan⁴  Cristina Parpala⁵  Ramona Draguţ⁴  Ioan Ancuta³  Andreea Diana Dragomir¹  Florin Rusu²  Georgiana Enache⁵  Mariana Jinga²  Emilia Rusu¹ 

[1] Healthy Nutrition Foundation, Bucharest, Romania;“Dr. Carol Davila” Clinical Central Military Emergency Hospital, Bucharest, Romania;Dr. I. Cantacuzino Clinical Hospital, Bucharest, Romania;“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania;“Prof. N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases - Bucharest, Romania

关键词: Body mass index;    HOMA-IR;    Lifestyle change;    Diet;    Hepatitis C;   

Others  :  805885
DOI  :  10.1186/1475-2891-12-119

 received in 2013-01-29, accepted in 2013-08-07,  发布年份 2013

【 摘 要 】

Background

In patients with chronic hepatitis C (CHC), obesity is involved in the pathogenesis of insulin resistance, fatty liver disease and progression of fibrosis. The objective of this study was to compare a normoglucidic low-calorie diet (NGLCD) with a low-fat diet (LFD) among participants with CHC. Aimed to measure the impact of dietary changes in reduction of insulin resistance, obesity but also in steatosis and fibrosis.

Methods

Randomized, controlled trial in three medical centers with assessments at baseline, 6 months and 12 months. Participants were patients over 35 years with chronic hepatitis C (n = 120) with BMI over 25 kg/m². We evaluated the effects of NGLCD vs. LFD in weight management and metabolic improvement. The primary endpoint was to measure the impact of dietary changes through nutritional intervention in reversibility of insulin resistance, obesity, steatosis, and fibrosis. We performed anthropometric measurements, fasting glucose profile, serum lipids, liver profile, blood count at baseline, 6 and 12 months. Steatosis was evaluated using ultrasonographic criteria. Liver fibrosis was non-invasively assessed.

Results

After 6 and 12 months of intervention, both groups had a significant decrease in caloric consumption. At 6 months, weight loss was greater in the NGLCD group (−5.02 ± 3.43 kg vs. −4.1 ± 2.6 kg; p = 0.002) compared to the LFD group. At 1-year, however, weight loss was similar in both groups (−3.9 ± 3.3 kg vs. −3.1 ± 2.6 kg; p = 0.139). At 12 months, fasting plasma glucose, fasting plasma insulin, and HOMA-IR had significant improvements in both groups. With both diets aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) decreased with significant differences; also there were significant improvements in AST/ALT ratio, Forns fibrosis index. The two diets were associated with reduction of both the prevalence and the severity of steatosis (all p < 0.001). At 12 months, total cholesterol, HDL-cholesterol, triglycerides improved in both groups (all p < 0.05).

Conclusions

The present study establishes the benefits of low-calorie diet and low-fat diet in management of patients with hepatitis C regarding improvement of insulin resistance, steatosis and also fibrosis.

Overweight or obese patients with CHC undergoing a lifestyle intervention (specific dietary intervention and physical activity) for 1-year had significant improvements in body weight, lipid and hepatic profile.

Trial registration

PNCI2-3343/41008/2007

【 授权许可】

   
2013 Rusu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Helen ST, Jensen MD: Epidemiology of Hepatitis B and C Viruses: a global overview. Clin Liver Dis 2010, 14:1-21.
• [2]Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R, Simionov I, Vadan R, Parvulescu I, Bancila I: Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005, 14:109-115.
• [3]Lonardo A, Ballestri S, Restivo L, Adinolfi L, Loria P: Hepatitis C and cardiovascular risk: facts and controversies. Hot Topics In Viral Hepatitis 2012, 24:27-35.
• [4]World Health Organization: Obesity: preventing and managing the global epidemic: report of a World Health Organization Consultation. Geneva, Switzerland: World Health Organization; 1997.
• [5]Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J: The National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002, 88:1882-1888.
• [6]Friedewald WT, Levy RI, Fredrickson DS: Estimatión of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [7]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [8]World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva; 1999.
• [9]Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
• [10]International Diabetes Federation: The IDF Worldwide Definition of the Metabolic Syndrom. 2005.
• [11]Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
• [12]Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS-F: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
• [13]Lewis JR, Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010, 55:560-578.
• [14]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 2009, 150(9):604-612.
• [15]U.S. Department of Agriculture: Center for Nutrition Policy and Promotion. 2008. http://MyPyramid.gov webcite
• [16]Food and Nutrition Board, Institute of Medicine: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids,Cholesterol, Protein, and Amino Acids (Macronutrients). [prepublication version]. Washington, DC: National Academy Press; 2002.
• [17]Corish C: Nutrition and liver disease. Topics Clin Nutr 1997, 55:17-20.
• [18]Gapinski MA, Zucker DM: Factors influencing the development of a hepatitis C exercise protocol: a literature review. Gastroenterol Nurs 2005, 28(Suppl 3):10-18.
• [19]Shronts E, Fish J: Hepatic failure. In Nutrition Support Dietetics: Core Curriculum. 2nd edition. Edited by Gottschlich MM, Matarese LE, Shronts EP. Silver Springs, MD: ASPEN Publishers; 1993:311-326.
• [20]Raup SM, Kaproth P: Hepatic failure. In Contemporary Nutrition Support Practice. Edited by Matarese LE, Gottschlich MM. Philadelphia, PA: WB Saunders Company; 1998:441-446.
• [21]Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hébuterne X: Resting energy expenditure in chronic hepatitis C. J Hepatol 2000, 33(4):623-627.
• [22]McCullough AJ, Teran JC, Bugianesi E: Guidelines for nutritional therapy in liver disease. In ASPEN Nutritional Support Practice Manual. Edited by Klein ES. Silver Springs, MD: American Society for Parenteral and Enteral Nutrition; 1998:1-12. 12
• [23]American Dietetic Association, Dietitians of Canada: Manual of Clinical Dietetics. 6th ed. 2000. ADA and DC
• [24]Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J: Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000, 132:853-861.
• [25]Moher D, Schulz KF, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991.
• [26]Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L: A low carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003, 348:2074-2081.
• [27]Matei C, Pop I, Jurcut R, Suceveanu M, Predescu D, Nechita E, Ionescu P, Ciovica D, Ginghina C: ROmanian multicentric study of the prevalence of metabolic syndrome–ROMES. Hellenic J Cardiol 2008, 49:303-309.
• [28]Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ: Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Res Clin Pract 2007, 75:320-326.
• [29]Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS: Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003, 98:2064-2071.
• [30]Lonardo A, Ballestri S, Adinolfi LE, Violi E, Carulli L, Lombardini S, Scaglioni F, Ricchi M, Ruggiero G, Loria P: Hepatitis C virus-infected patients are ‘spared’ from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol 2009, 23:273-278.
• [31]Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P: Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011, 12:2215-2234.
• [32]Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ, Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with Type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
• [33]Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
• [34]Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215-1219.
• [35]Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
• [36]Andersen T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12:224-229.
• [37]Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P: Ultrasonographic fatty liver indicator, a novel score which rules aut NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012, 32:1242-1252.
• [38]Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S: Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol 2012. http://www.ncbi.nlm.nih.gov/pubmed/23273500 webcite
• [39]Berger BG, Owen DR: Relation of low and moderate intensity exercise with acute mood change in college joggers. Perceptual &Motor Skills 1998, 87:611-621.
• [40]Lluch A, Hubert P, King NA, Blundell JE: Selective effects of acute exercise and breakfast interventions on mood and motivation to eat. Physiol Behav 2000, 68:515-520.